Wyeth is working hard to bring new products into the menopausal market after losing their leading edge when Premarin got such bad press out of the Women's Health Initiative.
Investigators recently reported that desvenlafaxine, a metabolite of Effexor that will be dubbed Pristiq had a significant effect on hot flashes and sleep disturbances associated with dwindling estrogen levels during the transition into menopause. Dr. Margery Gass called it "a major breakthrough for women: the first nonhormonal therapy for menopausal symptoms."
The results of these studies presumably will soon be presented to the FDA as Wyeth seeks approval to bring Pristiq to pharmacy shelves.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment